MAGEA4 and familial pancreatic carcinoma: Due to its absence in normal tissues, MAGE-A4 remains a potential immunotherapeutic target for pancreatic cancer, with strategies like MAGE-A4 peptide vaccines under development (Bert et al. 2002).